anti-mv-a inos monoclonal antibody

The anti-MV-A iNOS monoclonal antibody (rHJ mAb) is an investigational recombinant humanized IgG1,kappa monoclonal antibody developed for the treatment of sepsis. It specifically targets microvesicle-associated inducible nitric oxide synthase (MV-A iNOS), a form of the iNOS enzyme that circulates in the blood within microvesicles during the inflammatory cascade. Unlike intracellular iNOS, MV-A iNOS contributes to systemic pathology by producing excessive quantities of nitric oxide at sites distant from the primary infection, leading to cellular damage and organ dysfunction. The rHJ mAb was engineered by grafting murine complementarity-determining regions (CDRs) into a human IgG1 framework and is expressed in CHO cells. Preclinical studies in mouse models of sepsis (including LPS, TNFα, and MV-A iNOS challenges) have demonstrated that the antibody can significantly improve survival rates in a time- and dose-dependent manner, rescuing up to 80% of animals when administered early.

Other names

recombinant humanized anti-microvesicle-associated iNOS IgG1,kappa monoclonal antibodyhumanized anti-MV-A iNOS mAb